Latest Protein kinase inhibitor Stories
FARMINGTON, Conn., July 10, 2012 /PRNewswire-iReach/ -- More companies are investing in kinase inhibitor research to address issues such as resistance, selectivity versus safety, developing lead compounds, and integrating chemistry and biology into development, as well as utilizing the latest technologies and techniques such as fragment- and structure-based design to develop new products. Having accurate market data and analysis is essential to companies that wish to compete on...
FARMINGTON, Conn., June 25, 2012 /PRNewswire-iReach/ -- The enzyme inhibitors industry in emerging markets has significant potential, in contrast to mature markets where growth is significantly slower. Having accurate market data and analysis is essential to companies that wish to compete on the global stage. With premium market research from the world's leading publishers, Global Information Inc. helps businesses stay on the cutting edge with the best forecasts, research, and...
RESEARCH TRIANGLE PARK, N.C., June 14, 2012 /PRNewswire/ -- TeraDiscoveries, Inc., announced today the identification of the first six biological targets for which the company is designing new drug candidates. This development follows the formation of a strategic relationship TeraDiscoveries has established with Microsoft Corp. Microsoft is providing support and cloud computing time on Windows Azure that TeraDiscoveries is applying to identify inhibitors of 25 top biological...
RIDGEFIELD, Conn., June 4, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company's pivotal Phase III clinical trial, LUX-Lung 3, investigating afatinib as a first-line treatment in patients with stage IIIb or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, met its primary endpoint of progression-free survival (PFS). The study evaluated 345 patients with NSCLC across a variety of...
SAN DIEGO and JERUSALEM, May 17, 2012 /PRNewswire/ -- Ambit Biosciences and Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) ("Teva") today announced the clearance of an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) for CEP-32496, a novel BRAF (V600E) kinase inhibitor. The IND filing was based upon promising therapeutic potential for this agent, as evidenced by data revealed in recent publications in the Journal of Medicinal...
RIDGEFIELD, Conn., May 16, 2012 /PRNewswire/ -- Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012. LUX-Lung 3, which compares the investigational oral,...
ROCKVILLE, Md., May 15, 2012 /PRNewswire/ -- EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO) The Company reported a net loss for the first quarter of approximately ($2.5 million), or ($0.23) per share, compared with a net loss of ($2.6 million), or ($0.25) per share, for the same period last year. The Company did not...
ROCKVILLE, Md., May 10, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has received notice from the Nasdaq Stock Market indicating that, based on the Company's completed financing described in the Company's Form 8-K dated May 4, 2012, the NASDAQ staff has determined that the Company complies with Listing Rule 5550(b). (Logo:...
DIEPENBEEK, Belgium, May 8, 2012 /PRNewswire/ -- Local ROCK Inhibition Highly Effective in Lowering IOP in Glaucoma Model While Avoiding Hyperemia Amakem NV, a kinase platform company focusing on ophthalmology, presented key preclinical data on its potent, locally active Rho Kinase (ROCK) inhibitor AMA0076 at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held at Fort Lauderdale, US from 6 - 10 May. The ARVO meeting is the...
LUXEMBOURG, May 3, 2012 /PRNewswire/ -- Creabilis SA, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, announces today that Dr Simon Russell has been appointed as Chief Business Officer. Dr Russell joins Creabilis from Novartis Pharma AG where he held a number global strategic marketing roles and most recently Head of Global Marketing for ILARIS (canakinumab). He was previously Head of Strategic...
